SEC Tracker
Get the app

Aspira Women's Health AWHL

Aspira Women's Health Q3 FY23: revenue $2.2M; diluted EPS −$0.48

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Aspira Women's Health reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$2.2MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$4.7MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.48No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$5.1MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations$3.3MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Aspira Women's Health files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2835 and related industry codes: the same peer list as the financial tables.

  1. Creative Medical Technology Holdings CELZ public float $5M, Jun 30, 2025
  2. Target Group CBDY public float $5M, Jun 30, 2025
  3. Soligenix SNGX public float $5M, Jun 30, 2025
  4. Matinas BioPharma Holdings MTNB public float $5M, Jun 30, 2025
  5. Viskase Holdings ENZN public float $5M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.